Cargando…

A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma

Active specific immunotherapy, using vaccines with autologous tumour cells and BCG, significantly reduces the rate of tumour recurrence in stage II colon cancer patients, while no clinical benefit has yet been observed in stage III patients. Adjuvant treatment with 5-Fluorouracil/Leucovorin is now c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baars, A, Claessen, A M E, Wagstaff, J, Giaccone, G, Scheper, R J, Meijer, S, Schakel, M J A G, Gall, H E, Meijer, C J L M, Vermorken, J B, Pinedo, H M, van den Eertwegh, A J M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375342/ https://www.ncbi.nlm.nih.gov/pubmed/11953877 http://dx.doi.org/10.1038/sj.bjc.6600254

Ejemplares similares

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.
por: Baars, J. W., et al.
Publicado: (1992)

Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
por: Scheithauer, W., et al.
Publicado: (1998)

Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy
por: Turksma, Annelies, et al.
Publicado: (2015)

Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
por: Honkoop, A. H., et al.
Publicado: (1996)

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.
por: Ogilvie, A. C., et al.
Publicado: (1994)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
por: van Cruijsen, H., et al.
Publicado: (2007)

Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
por: Baars, J. W., et al.
Publicado: (1992)

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
por: de Gruijl, Tanja D., et al.
Publicado: (2008)

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.
por: Honkoop, A. H., et al.
Publicado: (1998)

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
por: Schippinger, W, et al.
Publicado: (2007)

Comparative efficacy of 5flourouracil/calcium leucovorine versus 5flourouracil/calcium leucovorine plus oxaliplatin in the adjuvant treatment of colonic carcinoma in Kashmir
por: Shaiq, Hamid Deva, et al.
Publicado: (2013)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
por: Moehler, M, et al.
Publicado: (2005)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma
por: Bathe, Oliver F, et al.
Publicado: (2004)

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer
por: van den Broek, Evert, et al.
Publicado: (2018)

Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Additional Chemotherapy with 5-FU plus Leucovorin between Preoperative Chemoradiotherapy and Surgery Improved Treatment Outcomes in Patients with Advanced Rectal Cancer
por: Park, Song Ee, et al.
Publicado: (2019)

The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
por: Crozier, J E M, et al.
Publicado: (2006)

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
por: Taal, B G, et al.
Publicado: (2001)

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
por: Schippinger, W, et al.
Publicado: (2005)

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
por: Jansen, W. J., et al.
Publicado: (1998)

Modified bi‐weekly cetuximab‐cisplatin and 5‐FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients
por: Meirovitz, Amichay, et al.
Publicado: (2021)

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
por: Koster, Bas D., et al.
Publicado: (2019)

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
por: Cassidy, J, et al.
Publicado: (2006)

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care
por: van der Meijde, Elisabeth, et al.
Publicado: (2016)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
por: Perkhofer, L., et al.
Publicado: (2019)

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
por: Maring, J G, et al.
Publicado: (2002)

The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.
por: DeLap, R. J.
Publicado: (1988)

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
por: Papadimitriou, Christos A, et al.
Publicado: (2011)

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
por: Nehls, O, et al.
Publicado: (2002)

TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients
por: Fariña-Sarasqueta, A., et al.
Publicado: (2010)

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
por: Veronese, M L, et al.
Publicado: (2005)

Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain.
por: Broxterman, H. J., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_97ml3gr355e1c16fm6437asbam